Management may also involve correcting biochemical abnormalities associated with CKD–MBD by lowering phosphate levels, reducing calcium intake, and/or using calcimimetics such as cinacalcet, which increases the sensitivity of the calcium-sensing receptor (CaSR) and reduces PTH secretion. Here, PTH is linked to chronic kidney disease.